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INTRODUCTION 
Coronary artery disease (CAD) is the main cause of death, 
morbidity and disability in the world and their prevalence 
is highly increasing in developing countries. In CAD 
patients, acute coronary syndrome (ACS) has the most 
importance because of the high possibility of unpleasant 
cardiovascular events during follow-up was more in these 
patients. In 2008, 7.3 million (12.8%) out of 57 million 
deaths was because of myocardial infraction. In the United 
States, almost 650 thousand patients get new acute 
myocardial infraction (AMI) per year. The rate of early 
death (30 days) with AMI is about 30% and more than half 
of these cases occur before reaching to the hospital.1,2 
During the last two decades, the rate of the death of 
coronary disease is decreasing in developed countries, 
whereas it is increasing in developing countries which is 
mostly because of long lifetime, urbanization and lifestyle 
changes.3 
In the United States, the adjusted rate of death based age 
due to coronary disease has been declined to two third in 
four last decades which is the reflection of better diagnosis 
and reduce risk factors and also improvement of faster 
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treatments and interventions for control of heart diseases. 
ACS needs a precise diagnosis and early hospitalization 
and prognosis of patients is directly associated with on 
time conducting vascularization, so non diagnosis or 
delayed diagnosis can have disaster clinical effects. Triage 
and management of the patients with chest pain has to be 
done appropriately. In addition, early diagnosis of ACS 
decreases the rate of side effects and the risk of long-term 
relapse and finally leads to its low economic loads on 
health system. In general, ACS includes unstable angina 
(UA), myocardial infraction with and without increasing 
ST part (NSTEMI).4 Among these cases, STEMI requires 
more urgent intervention and early reperfusion to restore 
myocardial function and prevention of ischemia and 
myocardial necrosis. Proper reperfusion is done by 
thrombolysis or primary PCI which can decrease the size 
of infract, protect the left ventricle and improve the long-
term and short-term consequences of disease.5,6 Doing 
primary PCI is the strategy of selective reperfusion in 
STEMI patients and when it is done urgently and in first 
hours of MI, it is effective in re-establishment of blood 
flow and this method is useful for patients with 
contraindication of fibrinolytic therapy. It seems that this 
method is more effective than fibrinolysis in bypassing 
clogged arteries and when it is done by experienced stuff 
and in specialized centers, it will be with long-term and 
short-term results. In fact, the rate of intra hospital death 
of STEMI has significantly decreased by improving 
reperfusion method during these years and currently it is 
between 6% to 14%.7,8 Coagulation treatment should be 
done in patients under PCI to limit the side effects of 
ischemia. However, this treatment can increase the risk of 
bleeding which is strongly associated with intra hospital 
and late disasters. Despite of the known limitations for 
heparin, still the unfractionated heparin is the most 
common used anticoagulant during PCI.9 The primary aim 
of treatment with anticoagulant drugs, is bypassing and 
protecting the infracted artery with strategies of 
reperfusion. The secondary aim includes decreasing 
thrombosis creation and then decreasing the possibility of 
wall coagulation (coagulation in heart) or deep vein 
thrombosis (that each can cause pulmonary embolism). 
Existing information demonstrates that when heparin is 
added to aspirin or nonspecific thrombolytic drug for fibrin 
like streptokinase, the rate of death in patients decreased 
more. It seems that intravenous injection of heparin with 
aspirin and almost specific fibrinolytic drugs for fibrin 
leads thrombolysis to facilitate and infracted vein remains 
bypassed. 2 The aim of this study is to determine the effect 
of heparin prescription before primary PCI on long-term 
and short-term clinical and para clinical results and 
mortality of patients with acute coronary syndrome.  
METHODS 
This is a randomized clinical trial that has been done on 
196 patients with ACS which candidate to PCI surgery. 
The exclusion criteria included not receiving thrombotic 
medicine during past seven days, pregnancy, active 
bleeding, thrombocytopenia history with heparin, 
receiving heparin before hospitalization and 
thrombocytopenic patients. Patients randomly divided into 
two groups: intervention group (bolus 60-90u/kg heparin 
UFH in emergency) and control group (bolus 60-90u/kg 
heparin as hospital routine and during PCI). 
Clinical and para clinical results included: local side 
effects of angiography during hospitalization, coronal EF 
during hospitalization and 45 days after that, the rate of 
TIMI FLOW after operation and titer of coronal enzymes 
at first 24 hours and mortality after one month was 
recorded by a check list and compared in two groups. The 
patients signed a written consent for participating in study. 
Data were analyzed using statistical methods in SPSS.17. 
The P<0.05 was considered meaningful. 
RESULTS 
The average age of patients was 63.02±13.4 and age range 
was between 35-91. 142 patients were male (72.4%) and 
54 patients (17.6%) were female. The mean age of patients 
in case group was 63.02±14.50 and in control group was 
63.02±11.91. The average of Troponin in case group with 
35.9±19.2 significantly lower than control group with 
39.1±17.03. Increasing rate of second CTNI toward the 
basic (more than 5 units) in case group was 83% and in 
control group was 90.5% and the difference wasn't 
statistically meaningful. During hospitalization and 45 
days after PCI, most of patients had hospital LVEF 40-
50% and the difference between two groups was 
statistically meaningful (Figure 1 and Figure 2). 
 
Figure 1: LVEF levels of patients in two groups. 
The case group meaningfully had better rate of LVEF than 
control group during follow-up (Figure 3). TIMI FLOW 
before PPCI was grade 0-1 in 91.6% of control group and 
99% of case group (Figure 4).  
After conducting PPCI, TIMI flow improve significantly 
in both groups so that in 89% of case group and 96.8% 
control group, TIMI was in grade 3. All of the hematoma 
occurred in case group and the difference between two 
groups was not meaningful. 
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Figure 2: LVEF levels of patients 45 days after PPCI 
in two groups. 
 
Figure 3: LVEF levels changes in patients compare to 
before amount in two groups. 
 
Figure 4: Frequency of TIMI flow before PPCI in                  
two groups. 
In present study, in 10 (5.1%) of patients death cases was 
observed that 60% of them from case group and 40% of 
control group and the difference between two groups 
wasn't meaningful. 91 patients (47.7%) with one coronary 
artery and 104 patients (53.3%) with 2-3 coronary arteries. 
The frequency of mortality in cases with 2-3 VD was more 
than on artery but there was no meaningful difference 
between two groups. The patients with an artery had better 
primary LVEF than the patients with 2-3 VD (Figure 5). 
 
Figure 5: TIMI flow before PPCI by VD. 
DISCUSSION 
In this study 196 patient (72.4% male and 27.6% female 
with the age average of 63.02±13.4 years old) were 
evaluated. There wasn’t significant difference between 
control and case groups in term of variables such as age, 
sex and the maximum CTnI. Miyachi et al, show in their 
paper that STEMI patients had the average age of 67 years 
old and majority was male (75.5%). Male and upper age 
have been considered as risk factors for unpleasant 
consequences in STEMI.10 Similarly, it was observed in 
Cho et al. study that patient undergoing PPCI had the 
average age was 65 years old and mostly were male.11 It 
was observed in this study that following the treatment of 
patients generally LVEF have increasing and the cases 
with LVEF <30% decreased after PCI during 45-day 
pursuing and the cases with LVEF >50% increased. 
During comparison of hospital LVEF and during pursuing 
between two groups observed that LVEF below 30% and 
above 50% in case group is so much more than control 
group and 30-50% were more in control group. While the 
improvement of LVEF in case group was obviously more 
than control group. 
Ottervanger et al, express that without PCI and 
angioplasty, the function of left ventricle and LVEF 
significantly improved after treatment.12 Also, Stolfo et al, 
observed during study that LVEF didn't improved 
following STEMI and PPCI in 28% of patients. These 
patients had lower LVEF during hospitalization and less 
improvement in LVEF during follow up.13 It was observed 
in Zijlstra et al, study that the patients receiving pre 
hospital heparin obviously had higher LVEF comparing 
other groups.14 Verheugt et al, observed that early 
treatment of patients with high dose of heparin be with 
complete coronary reperfusion at considerable amount of 
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patients with AMI especially in patients who are treated 
below two hours, were associated.15 
In this study, it is observed that 0-1 TIMI flow before 
intervention obviously in case group was more than 
control group (99% versus 91.6%) but after intervention 
there was no significant difference between two groups 
(3% versus 1.1%). This expresses that the influence of 
primary PCI in treatment of STEMI patients and 
improvement of their clinical situation while heparin 
injection before PCI doesn't effect on the treatment. 
Zijlstra et al, observed that TIMI score in damaged artery 
in heparin group was higher than other group which be 
with higher angioplasty success.14 Chung et al, 
investigated that the evaluation of early prescription of 
heparin in emergency on patency of coronary artery and its 
clinical consequences in STEMI patients, observed that 
TIMI was higher in 2,3 scores in heparin-receiving groups. 
In fact, this study expresses that in STEMI patients, early 
heparin treatment in emergency leads to improvement 
coronary patency.16 
It is observed in this study that in case group in comparison 
to control group the rate of hematoma was higher (3.1% 
versus zero %) but not meaningful. The incidence rate of 
hematoma in different studies has been reported for 
different heparin receivers. In Stone et al. study, in heparin 
receiving patients, the major bleeding is occurred in 8.3% 
which was more than our study results. Also in Bonello et 
al. study the incidence rate of Hematoma in heparin group 
was more than B vali Rodin group (6.7% versus 3.4%).17,18 
In this study, the case group had more 30 day death in 
comparison to control group but difference was not 
statistically meaningful (6% versus 4.2%) and in fact it can 
be claimed that using heparin with bolus dose not effect on 
final outcome and the rate of patients' death. Also it was 
observed that the frequency of death among patients with 
2-3 clogged vein was high but not meaningful which 
higher death rate in case group is associated with number 
of clogged artery. In Steg et al. investigation there was no 
obvious difference of death rate between heparin receiving 
and B vali rodin group.19 Montalscat et al, observed that 
enoxaparin has no difference in death rate and operation 
success rate in comparison to heparin.20 In Stone et al, 
study, the reported rate of death for heparin group was 
3.1% which was similar to our study, whereas in Bonello 
et al. study the rate of death for heparin group was lower 
and reported about 1.1%.17,18 Zijlstra et al, observed that 
heparin prescription group in comparison with no heparin 
prescription group had lower 30-day death rate (1.6% 
versus 3.4%).14 Chung et al, showed that in STEMI 
patients, early heparin treatment in emergency improve 
coronary patency. 16 The difference between the findings 
of this study and other studies can be related to difference 
in the sample size, risk factors, angiographic 
characteristics and the time of reaching patients of pain 
start time to hospital and receiving treatment. For example 
in this study, heparin receiving patients had more coronary 
artery that completely affects the treatment and clinical 
outcomes of patients. 
CONCLUSION 
This study showed that, generally, doing primary PCI in 
STEMI patients has obvious improvement in blood flow 
of clogged vein and TIMI flow without receiving heparin. 
Receiving Heparin in these patients with increasing the 
improvement of clogged vein may lead to better LVEF 
improvement and finally a better function of left ventricle. 
Using bolus heparin is not be with high risk of bleeding 
and had no effect on the 30-day mortality rate of patients. 
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